Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Eli Lilly and Company
Scientific Title
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer